DxUpClose

About:

DxUpClose develops a point-of-care bacterial diagnostic that performs an antibiotic sensitivity test in 60 minutes.

Website: http://www.dxupclose.com

Twitter/X: DxUpClose

Top Investors: Golden Seeds, Green Park & Golf Ventures

Description:

DxUpClose, Inc. is young company developing a point-of-care bacterial diagnostic that will perform an antibiotic sensitivity test in sixty minutes. The product is designed to screen for specific bacteria, regardless if the sample has the targeted bacteria, it will count the bacteria that are there and perform antibiotic sensitivity tests - all within sixty minutes. At the end of the test, the product will securely send a list of effective antibiotics to the Healthcare worker’s email or smartphone, so results can be rapidly interpreted by a physician who can then either write a prescription or ePrescribe the appropriate antibiotic. This will reduce the delay in optimal patient care present today by one to three days. Their device is designed to weigh less than sixteen ounces, fit in a pocket, run on batteries and survive temperature extremes, making it easy to transport while still retaining its diagnostic reliability.

Total Funding Amount:

$1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Frisco, Texas, United States

Founded Date:

2009-01-01

Founders:

Clois Powell, Cyndi Nickel, James Biard

Number of Employees:

1-10

Last Funding Date:

2012-08-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai